BR9912117A - Uso de estimulador de captação de glicose para reduzir a apoptose - Google Patents

Uso de estimulador de captação de glicose para reduzir a apoptose

Info

Publication number
BR9912117A
BR9912117A BR9912117-4A BR9912117A BR9912117A BR 9912117 A BR9912117 A BR 9912117A BR 9912117 A BR9912117 A BR 9912117A BR 9912117 A BR9912117 A BR 9912117A
Authority
BR
Brazil
Prior art keywords
stimulator
glucose uptake
human
reduce
cells
Prior art date
Application number
BR9912117-4A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of BR9912117A publication Critical patent/BR9912117A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE ESTIMULADOR DE CAPTAçãO DE GLICOSE PARA REDUZIR A APOPTOSE" Método para reduzir ou prevenir a apoptose de células diferenciadas selecionadas a partir da lista consistindo de miócitos cardíacos, células pancreáticas beta, células endoteliais e células neuronais em mamífero humano ou não humano, cujo método compreende a administração, incluindo a administração intensa, de uma quantidade eficaz, não tóxica de um estimulador de captação de glicose a um mamífero humano ou não humano com necessidade disto.
BR9912117-4A 1998-07-21 1999-07-21 Uso de estimulador de captação de glicose para reduzir a apoptose BR9912117A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
BR9912117A true BR9912117A (pt) 2001-04-10

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912117-4A BR9912117A (pt) 1998-07-21 1999-07-21 Uso de estimulador de captação de glicose para reduzir a apoptose

Country Status (26)

Country Link
EP (2) EP1516617A2 (pt)
JP (1) JP2002521326A (pt)
KR (1) KR20010079551A (pt)
CN (1) CN1310620A (pt)
AP (1) AP2001002036A0 (pt)
AT (1) ATE288746T1 (pt)
AU (1) AU5053799A (pt)
BG (1) BG105250A (pt)
BR (1) BR9912117A (pt)
CA (1) CA2338211A1 (pt)
DE (1) DE69923687T2 (pt)
DK (1) DK1098639T3 (pt)
EA (1) EA200100165A1 (pt)
ES (1) ES2237929T3 (pt)
HK (1) HK1037865A1 (pt)
HU (1) HUP0103199A3 (pt)
ID (1) ID26986A (pt)
IL (1) IL140664A0 (pt)
NO (1) NO20010292L (pt)
OA (1) OA11579A (pt)
PL (1) PL345627A1 (pt)
PT (1) PT1098639E (pt)
SI (1) SI1098639T1 (pt)
SK (1) SK1012001A3 (pt)
TR (1) TR200100207T2 (pt)
WO (1) WO2000004890A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
SI1098639T1 (pt) 2005-08-31
NO20010292D0 (no) 2001-01-18
EA200100165A1 (ru) 2001-08-27
CN1310620A (zh) 2001-08-29
ES2237929T3 (es) 2005-08-01
EP1098639A1 (en) 2001-05-16
PL345627A1 (en) 2002-01-02
BG105250A (en) 2001-11-30
HK1037865A1 (en) 2002-02-22
AU5053799A (en) 2000-02-14
DE69923687D1 (de) 2005-03-17
DK1098639T3 (da) 2005-06-13
EP1098639B1 (en) 2005-02-09
WO2000004890A1 (en) 2000-02-03
ID26986A (id) 2001-02-22
DE69923687T2 (de) 2006-04-06
PT1098639E (pt) 2005-06-30
OA11579A (en) 2004-06-01
AP2001002036A0 (en) 2001-03-31
IL140664A0 (en) 2002-02-10
HUP0103199A2 (hu) 2002-05-29
SK1012001A3 (en) 2001-08-06
KR20010079551A (ko) 2001-08-22
CA2338211A1 (en) 2000-02-03
EP1516617A2 (en) 2005-03-23
NO20010292L (no) 2001-03-08
JP2002521326A (ja) 2002-07-16
TR200100207T2 (tr) 2001-05-21
ATE288746T1 (de) 2005-02-15
HUP0103199A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
NO985232D0 (no) Androstenderivater
EA200101089A1 (ru) Новый способ лечения
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK0998287T3 (da) Anvendelse af levobupivacain
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
MA26777A1 (fr) Inhibiteurs d'aminotransferase dependante d'aminoacide en chaine ramifiee et leur usage dans le traitement de la retinopathie diabetique.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
BR9912117A (pt) Uso de estimulador de captação de glicose para reduzir a apoptose
PT1058544E (pt) Inibicao da actividade do tnf
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
WO2003072606A3 (en) Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
WO2001045714A3 (en) Formulations of adenosine a1 agonists

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1919 DE 16/10/2007.